Chemoinformaics analysis of 3,4-Dihydroxybenzoic acid
| Molecular Weight | 154.121 | nRot | 1 |
| Heavy Atom Molecular Weight | 148.073 | nRig | 19 |
| Exact Molecular Weight | 154.027 | nRing | 1 |
| Solubility: LogS | -3.937 | nHRing | 0 |
| Solubility: LogP | 4.408 | No. of Aliphatic Rings | 0 |
| Acid Count | 1 | No. of Aromatic Rings | 1 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 17 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 11 | No. of Aromatic Carbocycles | 1 |
| nHetero | 4 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 6 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 7 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 6 |
| No. of Oxygen atom | 4 | No. of Arom Bond | 6 |
| nHA | 3 | APOL | 18.8988 |
| nHD | 3 | BPOL | 6.88724 |
| QED | 0.747 |
| Synth | 3.251 |
| Natural Product Likeliness | 2.139 |
| NR-PPAR-gamma | 0.906 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0.017 |
| Pgp-sub | 0.033 |
| HIA | 0.021 |
| CACO-2 | -4.741 |
| MDCK | 0.0000118 |
| BBB | 0.018 |
| PPB | 0.936057 |
| VDSS | 0.708 |
| FU | 0.0792679 |
| CYP1A2-inh | 0.614 |
| CYP1A2-sub | 0.937 |
| CYP2c19-inh | 0.962 |
| CYP2c19-sub | 0.461 |
| CYP2c9-inh | 0.916 |
| CYP2c9-sub | 0.951 |
| CYP2d6-inh | 0.865 |
| CYP2d6-sub | 0.806 |
| CYP3a4-inh | 0.815 |
| CYP3a4-sub | 0.339 |
| CL | 14.177 |
| T12 | 0.482 |
| hERG | 0.06 |
| Ames | 0.047 |
| ROA | 0.684 |
| SkinSen | 0.858 |
| Carcinogencity | 0.097 |
| EI | 0.244 |
| Respiratory | 0.927 |
| NR-Aromatase | 0.615 |
| Antiviral | No |
| Prediction | 0.803835 |